Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Skipping meal tied to increased fat deposition in type 2 diabetes
Among patients with type 2 diabetes (T2D), those who eat two meals per day exhibit higher greater intrapancreatic fat deposition than those who consume three meals per day, a study has found.
Skipping meal tied to increased fat deposition in type 2 diabetes
15 Oct 2022First-line SGLT2 inhibitors, GLP1 receptor agonists need to cut price to be cost-effective
First-line treatment with sodium–glucose cotransporter-2 (SGLT2) inhibitors or glucagon-like peptide-1 (GLP1) receptor agonists improves outcomes in patients with type 2 diabetes (T2D), but to be cost-effective, the prices of these drugs must drop by at least 70 percent, suggests a study.
First-line SGLT2 inhibitors, GLP1 receptor agonists need to cut price to be cost-effective
15 Oct 2022DIY diabetes management with digital app facilitates better weight, blood sugar control
Self-management of diabetes through smartphone heath app engagement appears to bring positive changes in disease outcomes such as weight and blood sugar, according to data from the Diabetes Lifestyle Intervention using Technology Empowerment (D’LITE) study.
DIY diabetes management with digital app facilitates better weight, blood sugar control
14 Oct 2022Maternal ultra-processed food intake ups risk of childhood obesity
Mothers who regularly eat ultra-processed foods during the child-rearing period appear to increase the risk of overweight or obesity in their children, irrespective of maternal and offspring lifestyle risk factors, a study has shown.
Maternal ultra-processed food intake ups risk of childhood obesity
14 Oct 2022Sotagliflozin may offer cardiorenal protection for adults with T1D
Using the Steno T1 Risk Engines, the dual SGLT*1 and SGLT2 inhibitor sotagliflozin showed potential in reducing the risk of cardiovascular (CV) and renal disease in adults with type 1 diabetes (T1D).
Sotagliflozin may offer cardiorenal protection for adults with T1D
13 Oct 2022Metformin, ivermectin, fluvoxamine OUT for severe COVID-19 prevention?
The use of metformin, fluvoxamine, or ivermectin in an outpatient setting did not appear to prevent progression to severe COVID-19, according to results of the phase III COVID-OUT trial.
Metformin, ivermectin, fluvoxamine OUT for severe COVID-19 prevention?
11 Oct 2022Is food insecurity a predictor of childhood obesity?
In a systematic review, a link between food insecurity (ie, low or very low food security) and obesity or greater weight gain was observed in early childhood. Some studies have pointed to an association specifically in girls and in children experiencing food insecurity at multiple timepoints.